Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ACTILYSE 2 mg is substantial. |
Clinical Added Value
| minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE. |
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
mDXDWWqaHGmC4e2w
Listen
